ChristianaCare’s Gene Editing Institute has launched DECODR, Inc., a new for‑profit company created to expand access to one of the world’s leading software tools to evaluate the effectiveness of ...
In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for ...
Functional genomics is central to modern drug discovery, yet high attrition rates persist. In this article, Dr Salman ...
CRISPR gene therapy increases haemoglobin and fetal haemoglobin in sickle cell disease, reducing vaso occlusive events in ...
Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, ...
A research team led by Prof. HSING I-Ming (third left), Professor of the Department of Chemical and Biological Engineering (CBE), along with Prof. ZHAI Yuanliang (second right), Associate Professor of ...
Cathie Wood's ARKK ETF features Tesla, AMD, Coinbase, and CRISPR Therapeutics as top holdings. Discover the fund's focus on ...
JMIR Publications today featured two new stories in its News and Perspectives section, highlighting a shift toward proactive, ...
Live-cell breakthrough: Munich scientists created a method to repeatedly read genetic activity from living cells, enabling long-term study without cell destruction. CRISPR reimagined: Hong Kong ...
Insilico Medicine announced LabClaw, an intelligent laboratory operating system designed to enable autonomous coordination ...
Allogeneic hematopoietic cell transplantation (alloHCT) using tremtelectogene empogeditemcel (trem-cel), a CRISPR–Cas9–edited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results